Description  Claims  Drawing  Cited references 

US61665116B   [0001] 
WO199706802A1   [0193]  [0193] 
WO199611201A1   [0193]  [0193]  [0193] 
EP01346994A   [0193] 
WO1996011021A1   [0201] 
EP1346994A1   [0201] 

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer   [0151] 
Hydrolysis in Drug and Prodrug Metabolism : Chemistry   [0156] 
Pharmaceutical Salts: Properties, Selection, and Use   [0157] 
J Neuroimmune Pharmacol.   [0175] 
A beta-lactamase-dependent Gal4-estrogen receptor beta transactivation assay for the ultra-high throughput screening of estrogen receptor beta agonists in a 3456-well format   [0189] 
A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment   [0189] 
J Enzyme Inhib Med Chem.   [0193] 
Binding Structures and Potencies of oxidosqualene cyclase inhibitors with the homologous squalene-hopene cyclase   [0195]